Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal Cancer Cell.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.
Varghese Jr. becomes just the eighth Editor-in-Chief during the 119-year history of the JACS, where he will be tasked with driving innovation and inspiring the…
The NMPA has approved belzutifan for von Hippel-Lindau disease in RCC, CNS hemangioblastomas, or pNETs not requiring immediate surgery.
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
wednesday, february 26 continental breakfast 7-8 a.m. Keynote Session 4Â 8-8:30 a.m. Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California education…
RP1 plus nivolumab received breakthrough therapy designation from the FDA for the treatment of patients with PD-1 inhibitor–exposed advanced melanoma.
This qualitative study investigates the patient and caregiver experience of diagnosis, treatment, and living with recurrent oropharyngeal cancer and changes to function and quality of…
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’ re speaking with…
